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HIV controllers are rare individuals who spontaneously control HIV replication in the absence of antiretroviral therapy. To
identify parameters of the CD4 response that may contribute to viral control rather thanmerely reflect a persistently low
viremia, we compared the T helper profiles in two groups of patients with more than 10 years of viral suppression: HIV control-
lers from the Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) CO18 cohort (n 26) and efficiently
treated patients (n 16). Cells specific for immunodominant Gag and cytomegalovirus (CMV) peptides were evaluated for the
production of 10 cytokines and cytotoxicity markers and were also directly quantified ex vivo by major histocompatibility com-
plex (MHC) class II tetramer staining. HIV controller CD4 T cells were characterized by a higher frequency of gamma inter-
feron (IFN-) production, perforin/CD107a expression, and polyfunctionality in response to Gag peptides. While interleukin
4 (IL-4), IL-17, and IL-21 production did not differ between groups, the cells of treated patients producedmore IL-10 in response
to Gag and CMV peptides, pointing to persistent negative immunoregulation after long-term antiretroviral therapy. Gag293
tetramer-positive cells were detected at a high frequency (0.12%) and correlated positively with IFN--producing CD4 T cells
in the controller group (R 0.73; P 0.003). Tetramer-positive cells were fewer in the highly active antiretroviral therapy
(HAART) group (0.04%) and did not correlate with IFN- production, supporting the notion of a persistent immune dysfunc-
tion in HIV-specific CD4 T cells of treated patients. In conclusion, HIV controllers maintained a population of highly efficient
Th1 effectors directed against Gag in spite of a persistently low antigenemia, while patients treated in the long term showed a loss
of CD4 effector functions.
HIV controllers are rare individuals who spontaneously con-trol HIV replication in the absence of antiretroviral therapy.
They can maintain a viral load below the detection threshold of
standard assays (50 copies HIV RNA/ml plasma) for decades
and show a very low risk of progression to AIDS (4, 23). Converg-
ing evidence indicates that HIV controllers have developed par-
ticularly efficient cellular antiviral responses, which can maintain
an active control of the infected target cell population in the long
term. HIV controller CD8 T cells have the capacity to efficiently
suppress HIV replication in autologous CD4 T cells in vitro (48,
64) and are thought to play a key role in HIV control (reviewed in
references 1, 3, 15, and 28).
The contribution of CD4 T cells to HIV control remains
more debated (9, 34, 45, 56). In response to HIV antigens, HIV
controllers maintain a central memory CD4 T cell population
with a remarkable proliferative capacity, which is associated with
an efficient secretion of interleukin 2 (IL-2) (19, 26, 58, 81) and
with the inactivation of proapoptotic molecules (73). A high pro-
liferative capacity of HIV-specific CD4 T cells can also persist in
patients who were treated very early in the primary infection stage
(62). However, most of the treated patients with good CD4 pro-
liferation and IL-2 secretion failed to control HIV replication
upon therapy interruption (34, 40), indicating that IL-2 responses
alone were insufficient to mediate HIV control. Several studies
have since indicated that the CD4 response pattern in HIV con-
trollers is qualitatively distinct from that of efficiently treated pa-
tients and is not just the consequence of a very low antigenemia.
Controller CD4 T cells have proven to be more “polyfunc-
tional” than those of treated patients, indicating a greater ca-
pacity to produce the cytokines/chemokines IL-2, gamma in-
terferon (IFN-), tumor necrosis factor alpha (TNF-) and
macrophage inflammatory protein 1 beta (MIP-1) simultane-
ously in the circulation (16, 19, 36, 52, 58), as well as in mucosal
tissues (20). The expression of the negative costimulatory mol-
ecule cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4)
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is lower on HIV-specific CD4 T cells of controllers than on
those of treated patients, suggesting that T cell receptor (TCR)-
dependent activation may be more efficient (39). In addition,
we recently reported the presence of a CD4 T cell population
with a high avidity for immunodominant Gag peptides in HIV
controllers, indicating the capacity to respond to minimal
amounts of virus (74). All these factors may promote efficient
CD4 helper function, which could then sustain a high-quality
CD8 response. Mouse models of chronic viral infections indi-
cate that CD4 T cell help is needed for efficient antiviral CD8
responses and that CD4 T cell depletion causes virus-specific
CD8 T cells to adopt an exhausted phenotype similar to that
seen in progressive HIV infection (78). A key issue that remains
is to pinpoint, among the spectrum of possible CD4 T cell
functions, those that may contribute to HIV control.
The T helper differentiation of HIV-specific CD4 T cells, de-
fined by the pattern of cytokines produced upon antigenic stimu-
lation, has been characterized in viremic and treated patients but
has not been fully explored in HIV controllers. The expanding
diversity of T helper types, including Th1, Th2, and Th17 and
follicular helper T cells (Tfh), as well as the recent recognition of
plasticity in T helper differentiation (reviewed in references 22, 82,
and 85) warrant further investigation of this issue. Production of
the Th1 cytokine IFN- has been consistently detected in specific
CD4 T cells from all categories of HIV-infected patients, but its
contribution to the suppression of HIV replication remains un-
clear, with high IFN- responses found at both extremities of the
progression spectrum, in HIV controllers as well as in highly vire-
mic patients (16, 20, 55, 58). HIV-specific CD4T cells producing
IL-17 have been detected in acute HIV infection, but were few or
absent afterwards in viremic and treated patients (5, 84). There
have been no reports so far of the presence of HIV-specific Th17
cells inHIV controllers. However, HIV infection is known to have
a clear impact on the total Th17 population, which is preferen-
tially depleted in the blood and intestinal mucosa of progressor
patients (5, 42, 46, 49, 59), but not of HIV controllers (12, 67).
Th17 depletion in progressor patients may play a role in the
chronic immune activation characteristic of HIV disease through
a loss of cytokines that promote the regeneration of epithelial
barriers, leading to compromised mucosal integrity and allowing
the crossing of inflammatory bacterial components (16).
The cytokine IL-21, which is produced almost exclusively by
CD4T cells, promotes B cell memory through the induction of B
cell isotype class switching and survival (75). Models of chronic
viral infection in mice have revealed the importance of IL-21 in
promoting the antiviral functions of CD8 T cells, in addition to
its role in humoral responses (18, 79). Recent studies have high-
lighted the possible contribution of this cytokine to HIV control,
with the findings that IL-21 in plasma correlates positively with
CD4 counts (33) and that IL-21 secreted by HIV-specific CD4 T
cells could induce a cytotoxic differentiation program with perfo-
rin induction in cognate CD8 T cells (11).Whether the frequen-
cies of IL-21-producing specific CD4 T cells differ in HIV con-
trollers and other patient groups remains debated, with one study
showing an increase in the controller group (11) and two studies
showing equivalent or lower levels (77, 83). However, in the pop-
ulation of patients with detectable viremia, the persistence of IL-
21-producing CD4 T cells is clearly associated with a beneficial
outcome, as indicated by an inverse correlationwith viral load (11,
83) and a positive correlation with the frequency of IL-2-specific
CD8 T cells (77).
We set out to characterize the T helper effector profile of HIV
controller CD4 T cells by measuring the expression of 10 cyto-
kines, chemokines, or cytotoxicitymarkers (perforin, CD107a) by
intracellular staining. In addition, we implemented the direct de-
tection of HIV-specific CD4 T cells by major histocompatibility
complex (MHC) class II tetramer staining ex vivo to obtain infor-
mation on their frequency and phenotype without the perturba-
tions associated with in vitro activation. While the use of MHC
class I tetramers for identifyingHIV-specific CD8T cells is wide-
spread, few studies have made use of the MHC class II tetramer
reagents,mostly due to the lower frequency ofHIV-specific CD4
T cells and to the complexity involved in producing stable recom-
binant HLA-DR molecules. These hurdles are being overcome
through the use of magnetic concentration or high-speed acqui-
sition of CD4 T cells, as well as progress in HLA class II expres-
sion strategies (13, 43, 47). Two pioneer studies found that CD4
T cells specific for Gag p24 epitopes could be detected by class II
tetramer staining in HIV-infected patients under therapy, at low
but detectable frequencies (between 104 and 105), and that
short-term therapy interruption led to a rebound in the frequency
of tetramer-positive (Tet) CD4 T cells (68, 69). In contrast,
prolonged viremia ultimately led to the loss of the Tet popula-
tion, suggesting the physical depletion of Gag-specific CD4 T
cells in progressor patients (69). We measured the frequency of
Tet CD4 T cells in HIV controllers to test the notion that these
rare patients could maintain a large population of HIV-specific
CD4T cells in spite of low antigenemia. TheGag p24 protein has
been shown to harbor immunodominant peptides that can be
recognized by up to half of HIV-infected patients, due in part to
the promiscuous binding of these peptides to diverse HLA-DR
and DQ molecules (35, 38, 60). By amplifying p24 Gag-specific
CD4 T cells in primary cell lines, we showed previously that the
peptide spanning amino acids 293 to 312 (Gag293) induced a
memory response in 90% of HIV controllers and treated pa-
tients who expressed at least one of 7 common HLA-DR alleles
(74). This broad recognition gave us the opportunity to compare
the frequencies and phenotypes of Gag293-specific cells by MHC
class II tetramer staining in a cohort of HIV controllers and in
patients who had received efficient antiretroviral therapy in the
long term. Both groups were characterized by viral suppression
(50 copies of HIV-1 RNA/ml) for over 10 years, allowing a com-
parative analysis of CD4 responses in two situations of persistently
low antigenemia.
Comparison of these two groups of patients showed that the
HIV controller status was associated with a higher frequency of
Th1 effectors, but not of Th2, Th17, or IL-21 effectors. The only
cytokinewith a higher production in the treated patient groupwas
IL-10, suggesting the presence of a negative immunoregulatory
state in the CD4 T cell compartment in spite of pharmacological
viral suppression. MHC class II tetramer analysis showed that
Gag293-specific CD4T cells persisted at a high frequency (103)
in HIV controllers but also in a subset of treated patients. The
frequency of Tet cells correlated positively with IFN- produc-
tion in the controller group but not in the treated patient group,
indicating high CD4 T cell functionality in HIV controllers and
persistent immune dysfunction of the HIV-specific CD4 T cell
compartment in patients treated in the long term.
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MATERIALS AND METHODS
Patients.TheHIV controller (HIC) group (n 26)was recruited through
the CO18 cohort set up by the AgenceNationale de Recherche sur le SIDA
et lesHépatitesVirales (ANRS). In the present study,HIV controllerswere
defined as HIV-1-infected patients who had been seropositive for 10
years, had received no antiretroviral treatment, and for whom 90% of
plasma viral loadmeasurements were undetectable by standard assays. All
HIV controllers included in the present study had current viral loads of
40 copies/ml. The group of efficiently treated patients (highly active
antiretroviral therapy [HAART] group; n 16) had received antiretrovi-
ral therapy for a minimum of 10 years and showed long-term viral sup-
pression with viral loads of40 copies of HIV RNA/ml. Treated patients
were recruited through the ANRS Seroco-Hemoco cohort, the Raymond
Poincaré Hospital (Garches, France), and the Bicêtre Hospital (Le Krem-
lin-Bicêtre, France). The healthy donor (HD) group (n 12) consisted of
anonymous healthy individuals who donated blood at the Etablissement
Français du Sang (EFS) (Paris, France). The study was promoted by the
ANRSunder number EP36 and approved by theComité de Protection des
Personnes IDF VII under number 05-22. All participants gave written
informed consent prior to blood sampling.
Whole-blood phenotyping. Expression of the activation markers
HLA-DR and CD38 were evaluated in CD4 T cell subsets by phenotyp-
ing in 100	l whole blood. Red blood cells were lysed with Lyse/Fix buffer
(BD Biosciences, San Jose, CA) and remaining leukocytes were labeled
with the following antibodies: anti-CD4-phycoerythrin (PE)-Texas Red
(Beckman Coulter, Fullerton, CA), anti-CD3-allophycocyanin (APC)-
eFluor780, anti-CD38-PerCP-eFluor710, anti-HLA-DR-PE-Cy7 (eBio-
science, San Diego, CA), anti-CD45RA-Horizon V450 and anti-CCR7-
Alexa Fluor 647 (AF647, BDBiosciences). Fluorescence was collected on a
9 color CyAn flow cytometer (Beckman Coulter) using Summit version
4.3 software.
Intracellular cytokine staining assay. HIV-specific stimulation was
performed by adding a 20-mer Gag peptide (Gag293-312, Gag263-282, or
Gag161-180) at 5 	g/ml to 2 
 106 freshly isolated peripheral blood
mononuclear cells (PBMC), in the presence of antibodies to the costimu-
latory molecules CD28 (0.5 	g/ml) and CD49d (0.5 	g/ml). CMV-spe-
cific stimulation was performed by adding an optimal pp65 20-mer pep-
tide chosen in the function of the HLA-DR genotype of the patient as
previously described (74). Negative controls consisted of 2 
 106 un-
stimulated PBMC. Positive controls were obtained by stimulating 2
 106
PBMC with 1 	g/ml of the superantigen Staphylococcal Enterotoxin B
(Toxin Technology, Sarasota, FL). Cells were stimulated for 14 h in the
presence of the secretion inhibitors monensin (2 	M) and brefeldin A (3
	g/ml). Cells were harvested, split in three, and stained for surface anti-
gens with the following antibodies: anti-CD107a-fluorescein isothiocya-
nate (FITC) (BD Biosciences), anti-CD3-APC-eFluor780 (eBioscience),
and anti-CD4-PE-Texas Red (Beckman Coulter). The Aqua Live/Dead
viability dye (Invitrogen) was added to exclude dead cells. Cells were fixed
and permeabilized using a fix/perm kit (eBioscience) according to the
manufacturer’s instructions. Intracellular cytokine staining was detected
with anti-IL-21-PE, anti-IL-4-PE, anti-MIP-1-PE, anti-IFN--PE-Cy7,
anti-IL-2-APC (all from BD Biosciences), anti-IL-17-AF488, anti-IL-10-
eFluor450, anti-TNF--eFluor450 (all from eBioscience), and anti-Per-
forin-PerCP clone B-D48 (Gen-PROBE). Fluorescence was collected on a
CyAn flow cytometer, with a minimum of 250,000 events collected in the
lymphocyte gate for each sample.
Flow cytometry data analysis. Flow cytometry data were analyzed
using FlowJo software (version 8.8.7; Tree Star, Ashland, OR). Intracellu-
lar cytokine production was evaluated in the live (Aqua) CD3 CD4
lymphocyte gate. The percentage of cytokine-producingCD4T cells was
determined after subtracting the percentage of cytokine-positive events in
unstimulated controls. Responses below the level of 0.01% cytokine-pro-
ducing cells after background subtraction were considered negative.
Polyfunctionality was assessed for a first panel of 5 functions that
included the production of IFN-, IL-2, MIP-1, TNF-, and CD107a.
The second panel included 4 functions, corresponding to the production
of IFN-, IL-10, IL-17, and IL-21. For each panel, the combinations of all
Boolean gates were generated in Flowjo, and the data were converted in
Microsoft Excel to the matrix symmetric positive definite (SPD) format.
The data were then analyzed and graphically represented using SPICE
software version 5.21, downloaded from http://exon.niaid.nih.gov. The
threshold for cytokine positivity was 0.01%. Comparison of distributions
was performed using Student’s t test and a partial permutation test as
described previously (61).
MHC class II tetramer labeling. At initiation of the study, HIV con-
trollers and treated patients were genotyped for HLA-DRB1. Patients
were included in the tetramer study if their genotype matched at least one
of the 6 HLA-DRB1 alleles available for MHC class II tetramer studies.
This panel allowed the analysis of70% of Caucasian patients (10). PE-
labeled tetramers for the DRB1*0101, DRB1*0301, DRB1*1501 and
DRB5*0101 alleles were obtained through the NIH Tetramer Facility at
Emory University. HLA-DRB1*0401, DRB1*0701, and DRB1*1101 bio-
tinylated monomers were produced in insect cell cultures as previously
described (44, 51). Monomers were loaded with 0.2 mg/ml peptide by
incubation at 37°C for 72 h in the presence of 2.5 mg/ml n-octyl--D-
glucopyranoside and 1mMPefabloc SC (Sigma-Aldrich). Peptide-loaded
monomers were tetramerized using APC- or PE-conjugated streptavidin
(eBioscience). To each tetramer loaded with an HIV-1 Gag or a CMV
pp65 peptide corresponded a control tetramer loaded with the class II-
associated invariant chain peptide (CLIP).
CD4 T cells specific for the Gag293 peptide FRDYVDRFYKTLRAE
QASQE (spanning amino acids 293 to 312 inHIV-1Gag)were detected by
ex vivoMHC class II tetramer labeling for all the patients included in the
tetramer study. CD4 T cells specific for CMV pp65 were detected with
tetramers loaded with an optimal peptide chosen in the function of the
HLA-DR genotype of the patient, as previously described (74). The CMV
peptides used corresponded to amino acids 41 to 55, 177 to 191, 281 to
295, 489 to 507, and 509 to 523 within the pp65 protein.
For each MHC class II tetramer labeling, 6 
 106 PBMC were incu-
bated with 4 	g/ml PE-conjugated tetramer for 90 min at4°C in phos-
phate-buffered saline (PBS) with 1%bovine serum albumin (BSA) and 10
mM sodium azide. Surface marker antibodies CD3-AF780-APC and
CD38-PerCP-eFluor710 (from eBioscience), CD45RA-V450 Horizon,
CD8-FITC, CD14-FITC, CD19-FITC, and CCR7-AF647 (all from BD
Biosciences), CD4-PE-Texas Red (Beckman Coulter), and the Aqua Live/
Dead viability dye were added for the last 20 min of labeling. When APC-
conjugated tetramers were used, CCR7-PE (BD Biosciences) was used
instead of CCR7-AF647. All events were acquired on a CyAn flow cytom-
eter at an average speed of 1,000 events/s and were analyzed using the
Flowjo software. The percentage of tetramer-positive (Tet) cells was
measured in the live (Aqua) CD3 CD4 CD8 CD14 CD19 gate.
Negative controls consisted of identical samples labeled with HLA-DR-
matched tetramers loaded with the CLIP. The percentage of Gag293-spe-
cific Tet cells was computed by subtracting the percentage of CLIP Tet
cells from that of Gag293 Tet cells. We verified that CD4 T cells from
healthy donorsmatched forHLA-DRB1 gaveminimal staining (0.01%)
with Gag293 tetramers. Due to limiting blood samples, not all patients
could be tested by both tetramer and intracellular cytokine staining (ICS)
assays.
Statistical analysis. Statistical analyses were performed with the
GraphPad Prism 5.0 software, using nonparametric statistical tests in all
cases. Differences in variables between groups were analyzed with the
Mann-Whitney U test. Correlations were analyzed with Spearman’s coef-
ficient R. All significant differences between groups (P  0.05) are re-
ported on data plots.
RESULTS
Immune activation of CD4 T cells in HIV controllers and
treated patients.We set out to compare CD4 T cell phenotypes
and functions in two groups of HIV-1-infected patients charac-
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terized by long-term control of HIV infection (Table 1). The HIV
controllers (HIC group,n 26) had shown a spontaneous control
of HIV replication for over 10 years, while treated patients
(HAART group, n  16) had received efficient antiviral therapy
that led to pharmacological control of HIV for over 10 years. Pa-
tients in both groups had an undetectable viral load by standard
assays (40 copies HIV-1 RNA/ml plasma). Both groups were
also comparable in terms of patient age (median, 52 years in the
HIC group versus 49 years in theHAART group), of the estimated
duration of HIV-1 infection (median of 18 years in both groups),
of CD4T cell counts (median, 754/mm3 in theHIC group versus
765/mm3 in the HAART group), and of CD4 T cell percentages
(median, 53.6% in the HIC group versus 49.9% in the HAART
group). The treated patients had a median CD4 nadir of 227 cells/
mm3, which was slightly higher than that reported for historical
controls in observational cohorts (17, 41) and may have been a
factor in the efficient immune reconstitution in these patients
(80). The similarly high CD4 T cell counts in the HIC and
HAART groups at the time of study ensured that immune differ-
ences due to the homeostatic response to CD4 lymphopenia were
minimal.
Immune activation of CD4 T cells, as measured by the com-
bined expression of HLA-DR and CD38, did not differ signifi-
cantly between theHIC andHAART groups (Table 2). Analyses of
the percentages of HLA-DR CD38 cells in the naive (Nv), cen-
tral memory (CM), and effector memory (EM) CD4 T cell sub-
sets defined by the CD45RA and CCR7 markers did not reveal
significant differences either (Table 2). However, both HIC and
HAART CD4 T cells showed signs of immune activation com-
pared to those of healthy blood donors (HD). In particular, ex-
pression of HLA-DR and CD38 was significantly increased in the
CD4 EM compartment of both patients groups compared to the
HD group (P 0.01 for HIC versus HD; P 0.0005 for HAART
versusHD) (Table 2). Thus, therewere signs of persisting immune
activation in HIV controllers and treated patients in spite of the
long duration of viral suppression and the relatively high CD4 T
cell counts in both groups.
Th1 differentiation of Gag-specific CD4T cells inHIV con-
trollers. To determine the T helper phenotype of Gag-specific
CD4 T cells, we analyzed their cytokine production pattern by
intracellular staining. Responses were measured to three peptides
(Gag293, Gag263, and Gag161) that induce immunodominant
CD4 responses in amajority ofHIV-1 infected patients (35, 38, 60,
74). The panel of cytokines analyzed included those typical of Th1
cells (IFN-, TNF-, MIP-1), Th2 cells (IL-4), and Th17 cells
(IL-17). IL-21 was included as a marker of Th17 and recirculating
Tfh cells. IL-2 was included to detect cells with good proliferative
capacity and IL-10 to detect cells with immunoregulatory func-
tion. The combination of total perforin expression (clone D48)
and of the degranulation marker CD107a was used to detect
CD4 T cells with cytotoxic potential. Negative controls consist-
ing of healthy donor cells stimulated with Gag peptides are re-
ported in Fig. S1 in the supplemental material. As seen in repre-
sentative examples (Fig. 1A), CD4 T cells that produced both
IFN- and TNF-, or IFN- and IL-2, could be detected in HIV
controllers, while IFN- and IL-4, or IFN- and IL-17, stemmed
from separate producer cell populations. Examples of unstimu-
lated controls are reported in Fig. S2 in the supplementalmaterial.
Quantitation of intracellular cytokine production in responses
to the 3 immunodominant Gag peptides showed that only IFN-
production and perforin/CD107a expression were significantly
increased in the HIC group compared to the HAART group (P





(HAART, n 16) P value
Age (yr) 52 (37–69) 49 (35–60) NS
Duration of HIV-1 infection (yr) 18 (10–28) 18 (10–22) NS
Duration of antiretroviral treatment (yr) NA 10 (10–14)
Virus load (HIV-1 RNA copies/ml plasma) 40 40 NS
CD4 T cells (per mm3) 754 (315–1976) 765 (422–1534) NS
% of CD4 T cells in CD3 T cells 53.6 (31.4–72.1) 49.9 (15.4–79.1) NS
Nadir of CD4 T cells (per mm3) NA 227 (6–589)
% with HLA B57 or B27 (no. positive/no. tested) 65.4 (17/26) 10.0 (1/10) 0.0036
a Median (range) values are listed unless otherwise noted. P values were estimated with the nonparametric Mann-Whitney U test. NS, not significant (P 0.05); NA, not
applicable.
TABLE 2 Immune activation in CD4 T cellsa
Cells













Total T CD4 cells 2.5 (1.3–11.9) 3.5 (0.5–18.2) 1.5 (0.9–2.2) NS 0.01 0.002
Naive CD45RA CCR7 T CD4
cells
1.2 (0.6–11.0) 1.9 (0.0–6.3) 1.1 (0.3–3.1) NS NS NS
CM CD45RA CCR7 T CD4
cells
1.9 (0.8–5.9) 2.2 (0.4–20.7) 1.4 (0.7–2.9) NS NS 0.03
EM CD45RA CCR7 T CD4
cells
3.8 (1.1–16.4) 5.5 (0.5–11.9) 1.9 (0.7–2.5) NS 0.01 0.0005
a Median (range) values are listed. P values were estimated with the nonparametric Mann-Whitney U test. CM, central memory; EM, effector memory; NS, not significant.
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FIG 1 Intracellular cytokine production in patients’ CD4 T cells stimulated with Gag peptides. Intracellular cytokine staining (ICS) was done on PBMC
stimulated overnight with the immunodominant peptidesGag161, Gag263, andGag293. Cytokine productionwas evaluated in the live CD3CD4 population.
(A) Examples of ICS in CD4 T cells from patients stimulated with Gag293, Gag263, or Gag161. The first 7 plots show the production of TNF-, MIP-1, IL-2,
IL-4, IL-17, IL-21, and IL-10 combined with that of IFN-. The last plot on the right, second row, shows the combined expression of total intracellular perforin
andof the degranulationmarkerCD107a,whichwas used to determine the cytotoxic potential ofCD4Tcells. The patient identificationnumber and the peptide
used for stimulation are indicated above each plot. (B)Quantitation of the percentage of cytokine-producingCD4T cells detected inHIV controllers (HIC) and
treated (HAART) patients. The summed percentages of cytokine-positive cells in response to Gag161, Gag263, and Gag293 are listed. Horizontal bars indicate
the median values. Significant P values (0.05) obtained with the nonparametric Mann-Whitney U test are shown.
Persistent Th1 Effectors in HIV Controllers
October 2012 Volume 86 Number 19 jvi.asm.org 10665
0.0012 and P 0.03, respectively) (Fig. 1B). The trends for higher
IL-2 and IL-17 production in the HIC group did not reach statis-
tical significance. It was, however, interesting that IL-17-secreting
HIV-specific CD4 T cells could be detected at high levels in a
subset ofHIV controllers, given that these cells appear exceedingly
rare in progressor patients (5, 84). IL-4 remained undetectable in
the majority of patients of both groups, indicating that HIV-1
infection did not generally promote a Th2 differentiation pattern.
However, IL-4 could be detected at significant levels in a few pa-
tients (Fig. 1A, upper right plot). IL-21 production could be high
in a few patients but did not differ significantly between the two
groups. Intriguingly, IL-10 was the only cytokine that showed a
higher expression in the HAART group than in the HIC group
(P 0.027), suggesting a dampening of effector responses by this
immunoregulatory cytokine in treated patients. Taken together,
these findings indicated that HIV-specific CD4T cells from con-
trollers were characterized by a clear Th1 differentiation profile,
the presence of effector cells with cytotoxic potential, and the oc-
casional occurrence of Th17 differentiation.
Since certain MHC class I alleles are strongly associated with
HIV control (1, 3, 15, 28), we examined the possible influence of
the HLA B genotype on the level of Gag CD4 responses. HLA B
typing was performed for all HIV controllers and 10 of the treated
patients (Table 1). The percentages of patients carrying the pro-
tective HLA alleles B57 and B27 differed significantly between the
two groups (HIC, 65% B57 or B27; HAART, 10% B57 or
B27; P 0.0036), as expected. For further analysis, HIV control-
lers were subdivided in two subgroups (“B57 or B27” versus
“B57 and B27”), which were compared for cytokine responses
to Gag peptides.We did not detect significant differences for the 8
cytokines analyzed or for perforin/CD107a expression, suggesting
that the HLA B genotype was not a major determinant of the
HIV-specific CD4 response.
Immunoregulatory profile ofGag-specific andCMV-specific
CD4 T cells in long-term-treatment patients. Analysis of CD4
responses at the single peptide level provided the opportunity to
compare patient responses to the same epitope. The three immu-
nodominant Gag peptides analyzed were all able to induce diverse
cytokine responses in HIV-infected patients (Fig. 2A and C).
Gag293 induced significantly more IFN- in the HIC than in the
HAART group (P  0.02). Gag161 showed a trend for increased
IFN- and TNF- induction (P  0.052 and P  0.061) and
caused increased perforin/CD107a expression in the HIC group
(P  0.03). In contrast, the Gag263 peptide did not appear to be
associated with the induction of Th1 effector responses (IFN- or
perforin/CD107a), but rather showed nonsignificant trends for
increased IL-17 induction in the HIC group and increased IL-10
induction in the HAART group. These observations suggested
that the T helper profile of Gag-specific CD4T cells depended on
the type of patient but also, possibly, on the nature of the recog-
nized epitope.
As controls, responses to optimal peptides derived from the
CMVmatrix phosphoprotein pp65 were tested with the same cy-
tokine panel (Fig. 2B and D). The T helper pattern of pp65 re-
sponses was mostly Th1, with a predominant production of
IFN-, TNF-, andMIP-1 in both theHIC andHAART groups,
and equivalent cytokine production levels in both groups of pa-
tients. The one significant difference concerned IL-10 production,
which again proved to be higher in theHAARTgroup (P 0.003).
Thus, patients treated in the long term showed signs of a damp-
ened CD4 response to both HIV and CMV through the synthesis
of IL-10. Treated patients also showed a concomitant decrease of
Th1 effectors directed against HIV but not CMV. In contrast, HIV
controllers maintained efficient Th1 effector responses to both
viruses.
Higher polyfunctionality of Gag-specific CD4 Th1 cells in
HIV controllers. Polyfunctionality, i.e., the capacity to produce
multiple cytokines simultaneously, was first analyzed for a com-
bination of 5 markers (CD107a, IFN-, IL-2, MIP-1, and
TNF-) expressed predominantly in Th1 cells. This analysis was
carried out for Gag293-specific cells, since these could be detected
in the majority of patients. Among Gag293-specific CD4 T cells,
monofunctional cells were the most abundant, both in the HIC
and HAART group (Fig. 3A). However, the fraction of polyfunc-
tional cells expressing 2 to 4 markers was higher in the HIC group
than in the HAART group, the difference being significant for
bifunctional cells (P  0.05). Gag293-specific cells expressing all
of the 5 markers together were not detected. Detailed analysis of
the different marker combinations (Fig. 3B) highlighted the pres-
ence of a peak of tri-functional cells coexpressing IFN-, IL-2, and
TNF- that appeared characteristic of HIV controllers.
Polyfunctionality of Gag293-specific CD4 T cells was ana-
lyzed for a second panel comprising the 4 cytokines IFN-, IL-10,
IL-17, and IL-21 (Fig. 3C). The production of these 4 cytokines
was almost mutually exclusive, with a low frequency of bifunc-
tional cells, and an absence of tri- and quadrifunctional cells. The
slightly higher fraction of bifunctional cells in the HAART group
appeared to be due to the cosynthesis of IL-10 and IL-17 in a
subpopulation of Gag293-specific cells (Fig. 3D). Among mono-
functional cells, the proportion of IFN-- and IL-17-producing
cells was higher in the HIC group, while that of IL-10-producing
cells was higher in the HAART group. Thus, analysis of the
Gag293-specific response supported the notion of persistent CD4
effectors in HIV controllers, and of negative CD4 immunoregula-
tion in treated patients. The fact that IFN- and IL-17 were pro-
duced by distinct cells in HIV controllers indicated that Gag293-
specific cells had either a Th1 or a Th17 differentiation, but were
not of the mixed Th1/Th17 phenotype. Similarly, few of the Th17
cells simultaneously produced IL-21, a cytokine that has been as-
sociated with the reinforcement of Th17 differentiation (76).
Thus, a significant fraction of Th1 cells fromHIV controllers were
polyfunctional, but their Th17 cells appeared monofunctional.
Higher frequency of Gag293-specific cells inHIV controllers
as determined byMHC class II tetramer staining.We character-
izedGag293-specific CD4T cells byMHCclass II tetramer stain-
ing, in order to directly measure their frequency ex vivo. We fo-
cused the analysis on the Gag293 peptide, which could be loaded
onto 6 different tetramers (HLA DRB1*0101, DRB1*0401,
DRB1*0701, DRB1*1101, DRB1*1501, and DRB5*0101) due to
its promiscuous binding to HLA-DRmolecules (38). Aminimum
of 6 
 106 PBMC was used per tetramer labeling, in order to
ensure the detection of low-frequency-specific CD4 T cells with
a sensitivity threshold of 0.001%. The percentage of Gag293
tetramer-positive (Tet) cells was minimal in CD4 T cells of
healthy blood donors (0.01%), but could reach up to 0.5 to 1%
in both treated patients and HIV controllers, as shown on repre-
sentative examples (Fig. 4B). Thus, CD4 responses to this single
immunodominant Gag peptide could reach high frequencies,
even though the amount of Gag antigen present in patients was
minimal (viral load [VL] 40 copies in both groups).
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Comparison of both patient groups (Fig. 5A) showed a higher
frequency of Gag293 Tet cells in HIV controllers, with a median
value of 0.12% of CD4 T cells in the HIC group versus 0.04% in
theHAARTgroup (P 0.05).However, we noted awide variation
in Tet frequencies in theHAART group, with some of the treated
patients showing as many Gag293-specific cells as the best re-
sponders in the controller group. A similar phenomenon was ob-
served when testing tetramers loaded with optimal CMV pp65
peptides, with a trend toward lower responses in the HAART
group (P 0.1), but with a high individual variability (Fig. 5B).
The distribution of CD4 T cell subsets based on the CD45RA
and CCR7markers was analyzed in the Tet populations (Fig. 5C
and D). The Gag293 Tet population had a mixed phenotype,
with a predominant central memory subset (CM, CD45RA
CCR7) in the HIC as well as in the HAART groups and a lower
but detectable effector memory subset (EM, CD45RA CCR7).
Highly differentiated effectors (CD45RA CCR7) were too few
to be quantified, while a fraction of Tet cells appeared phenotyp-
ically naive (CD4R5ACCR7) (not shown). These cells also pre-
dominantly expressed CD27, raising the possibility of a reversion
of Gag-specific CD4 T cells to a fully naive phenotype. The phe-
notype of the CMV Tet population was also mixed, with a trend
towardmore CM and fewer EM cells in theHAART group than in
the HIC group, though the differences did not reach statistical
significance (P  0.13 and P  0.07, respectively). Expression of
the costimulatory marker CD27 was high in the CM Tet popu-
lation specific for Gag293, both in the HIC and in the HAART
group (medians of 82.2% and 71.4%, respectively). CD27 expres-
sion was lower in the EMTet population (medians of 57.4% and
of 49.2%), as expected, but still relatively high, indicating that
approximately half of the EM Tet cells corresponded to a transi-
tional memory population (Fig. 5E). Expression of CD27 in the
FIG2 Analysis of intracellular cytokine production to individual Gag andCMVpeptides. (A andC) Themedian percentage of cytokine-producing cells induced
by each of the three immunodominant Gag peptides is represented in stacked columns (Gag293, gray; Gag263, black; Gag161, white). (B and D) Cytokine
production induced by optimalCMVpeptides chosen in the function of patients’HLA-DRalleles are represented by the hatched bars.Median cytokine responses
that did not reach the detection threshold are represented by the midpoint between the threshold value of 0.01% and zero (0.005%). Significant differences
obtained in the Mann-Whitney U test are indicated by the asterisks.
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CMV Tet population was comparable to that seen in the
Gag293-specific population (Fig. 5F). Thus, CD27 expression was
maintained in specific CD4 T cells of both HIV controllers and
patients treated in the long term, which is indicative of preserved
costimulatory capacity and lack of immune exhaustion.
The activation status of the Tet populations could not be
evaluated with the HLA-DR marker, because anti-HLA-DR anti-
bodies cross-reacted with some of the tetramer reagents. Interest-
ingly, the CD38 activation marker showed a trend for higher ex-
pression in Gag293 Tet cells of HIV controllers than in those of
treated patients, with a P value close to significance in the CM
Tet subset (P 0.057) (Fig. 5G). CD38 expression did not differ
significantly in the CMV Tet populations between the two
groups, though again high CD38 expression was noted for a few
HIV controllers (Fig. 5H). These findings suggested a possible
increase of specific CD4 T cell activation for a subset of HIV
controllers. However, there were no signs of massive activation or
of immune exhaustion in the Tet populations.
Functional impairment of Gag293-specific cells in treated
patients. We then compared the frequencies of Gag293-specific
FIG 3 Polyfunctionality of Gag293-specific CD4 T cells. (A and B) Polyfunctionality analysis for the CD107a/IFN-/IL-2/MIP-1/TNF- panel. The colors in
the pie charts represent the proportions of monofunctional cells (dark blue), bifunctional cells (light blue), trifunctional cells (green), quadrifunctional cells
(yellow), and pentafunctional cells (orange) within the population of Gag293-specific CD4 T cells, as determined by ICS. The bar chart shows the frequency of
Gag293-specific cells in each functional category, with red bars corresponding to HIV controllers (HIC) and dark blue bars corresponding to treated patients
(HAART). *, significant difference in bifunctional cells between the HIC and HAART groups (P  0.05). (C and D) Polyfunctionality analysis for the
IFN-/IL-10/IL-17/IL-21 panel. The colors in the pie charts represent the proportions of monofunctional cells (dark blue), bifunctional cells (light blue),
trifunctional cells (green), and quadrifunctional cells (yellow) within the population of Gag293-specific CD4 T cells. The bar chart shows the frequency of
Gag293-specific cells in each functional category. These analyses were carried out with the SPICE 5.21 program.
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CD4T cells detected physically (by class II tetramer binding) and
functionally (by intracellular cytokine staining). Interestingly, the
percentage of Tet cells and that of IFN- cells correlated posi-
tively in the HIC group (R  0.73, P  0.003) but not in the
HAART group (R 0.33, P 0.05) (Fig. 6A and B). The median
ratio (interquartile range) of IFN--producing cells to Tet cells
was 0.28 (0.21 to 0.63) in the HIC group and 0.06 (0.00 to 0.43) in
theHAARTgroup, indicating that the functional response of Tet
cells from HAART patients was minimal. Similar analyses for
other cytokines did not yield significant correlations, with the ex-
ception of a positive association between Gag293 Tet and IL-17-
producing cells observed in the HIC group (R  0.72, P  0.02)
but not in the HAART group (Fig. 6C and D). Taken together,
these findings suggest that the vast majority of Gag293-specific
cells present in long-term-treatment patients fail to produce
IFN- upon antigenic restimulation, pointing to an impaired Th1
response. In contrast, Gag293-specific cells from HIV controllers
maintain an efficient Th1 effector function in spite of the very low
antigenemia present in these individuals.
DISCUSSION
HIV controller responses to immunodominantGag peptides were
characterized by the persistence of highly differentiated Th1 cells
with effector functions, as indicated by a higher frequency of IFN-
-secreting cells and of CD4 T cells with degranulation capacity.
The correlation between Gag293-specific cells detected by MHC
class II tetramer staining and IFN- secretion indicated that about
one-fourth of Gag-specific CD4 T cells maintained effector
function, even though the amount of Gag antigen driving effector
responses was minimal in vivo. In contrast, patients treated in the
long term,whohad equally low antigenemia, showed a downregu-
lation of Gag-specific CD4 effector responses, as indicated by a
lower frequency of cells with IFN- secretion or degranulation
capacity and a lower frequency of Gag293-specific cells detected
by class II tetramer staining. In support of this notion, Gag-spe-
cificCD4T cells that persisted in treated patients showed signs of
functional downregulation, as indicated by increased IL-10 secre-
tion and the failure of Gag293-specific cells to produce IFN-
upon restimulation. Thus, the Gag-specific response was main-
tained in a persistent effector state in HIV controllers, while it
appeared to be subjected to negative immunoregulation in treated
patients.
The differentiation of Gag-specific CD4 T cells from HIV
controllers proved to be predominantly Th1, rather than Th2,
Th17, or Tfh. A bias toward a Th1 effector response fits with the
expected pattern for an efficient response against an intracellular
pathogen such as HIV (85), but it should be noted that Th1 dif-
ferentiation alone cannot account for viral control, since IFN-
CD107a Th1 effectors are also abundant in viremic patients (16,
25, 55). Rather, it is the capacity to maintain a functional Th1
effector population in a situation of very low antigenemia that
FIG4 Detection ofGag293-specificCD4T cells byMHCclass II tetramer staining. (A)Gating strategy to detect Gag293-specific cells inCD4T cells. Tetramer
staining was analyzed in viable CD3 CD8 CD14 CD19 CD4 lymphocytes, starting from a minimum of 6 
 106 PBMC. (B) Examples of detection of
Gag293-specific cells with 4 different tetramers based on the DRB1*0101, DRB1*0701, DRB1*1101, and DRB5*0101 molecules. For each tetramer, the percent-
age of tetramer-positive (Tet) cells in CD4 T cells is indicated for one healthy donor (HD), one treated patient (HAART), and one HIV controller (HIC). A
negative control consisting of CD4 T cells labeled with a CLIP-loaded tetramer is shown for each of the HIV controllers tested (HIC-ctrl, right column).
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appears characteristic of HIV controllers. The comparison with a
group of patients treated efficiently in the very long term (more
than 10 years) was instrumental in highlighting this difference,
since other studies indicate that patients treated for a shorter pe-
riod of time maintain a degree of Th1 effector function, as indi-
cated by detectable IFN--specific CD4 T cells with degranu-
lation capacity (2, 50). The long duration of treatment in the
present study may also account for a degree of recovery of IL-2
responses in the HAART group and the lack of a significant dif-
ference in IL-2 production with the controller group. Consistent
FIG 5 Frequency and phenotype of Gag293-specific tetramer-positive CD4 T cells in HIV controllers (HIC) and treated patients (HAART). (A) The
percentages of tetramer-positive (Tet) CD4 T cells specific for Gag293 were compared in the HIC and HAART groups. (B) The percentages of Tet cells
specific for optimal CMV pp65 peptides were compared in the HIC and HAART groups. (C and D) The percentages of central memory (CM) (CD45RA
CCR7) and effector memory (EM) (CD45RA CCR7) CD4 T cells were analyzed in the Gag293 Tet population (C) and the CMV Tet population (D).
(E and F) The percentages of CD27 cells were analyzed in the CM and EM Gag293 Tet populations (E) and in the CM and EM CMV Tet populations (F).
(G and H) The percentages of CD38 cells were analyzed in the CM and EMGag293 Tet populations (G) and in the CM and EMCMVTet populations (H).
The horizontal bars indicate the median values. Significant P values (0.05) obtained with the nonparametric Mann-Whitney U test are shown.
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with this notion, a recent comparison of patients treated effi-
ciently for less than 3 years and more than 10 years showed that
prolonged therapy further improved CD4 proliferative responses,
while IFN- production by CD4 T cells remained minimal (24).
Thus, patients treated in the very long term show the expected
signature of a resolved viral infection with antigen clearance, with
a reappearance of IL-2-secreting memory CD4 T cells with pro-
liferative capacity and a loss of effector functions (25). HIV con-
trollers provide an exception to this pattern, as they appear to
maintain both IL-2 secretion and effector functions in the long
term in spite ofminimal antigenemia. Early studies have provided
evidence for a preserved central memory CD4 T cell compart-
ment with remarkable proliferative and IL-2 secretion capacities
in HIV controllers (19, 26, 58, 81). The notion of advanced effec-
tor differentiation has emerged in studies of CD8 T cell re-
sponses in HIV controllers, with the realization that these rare
patients harbored HIV-specific CD8 T cell with highly efficient
antiviral functions, associated with an increased loading of perfo-
rin and granzyme Bwithin cytotoxic granules (27, 29, 48, 64). The
present study suggests that advanced effector differentiation also
persists in the CD4 T cell compartment of HIV controllers. The
presence of a CD107 perforin CD4 T cell population raises
the possibility that Gag-specific CD4 T cells may have direct
cytotoxic potential and may contribute to the elimination of in-
fected cells, a property that has been documented in certain
chronic viral infections such as CMV (2, 8) and that characterizes
CD4 T cell clones from rhesus macaques able to control simian
immunodeficiency virus infection (63). A recent study suggests
that cytolytic CD4T cells may well play a role in the early control
of HIV replication, with the finding that expansion of HIV-spe-
cific CD107a CD4 T cells in the acute stage is associated with a
lower viral set point (70).
It was interesting that IL-17 production could be induced by
Gag peptides in about half of theHIV controllers, even though the
difference with the HAART group did not reach significance. Pre-
vious studies have shown that HIV-specific Th17 cells are exceed-
ingly rare in viremic and treated patients, except during the acute
infection stage (5, 84). The detection of Gag-specific Th17 cells in
HIV controllers is consistent with the preservation of the total
Th17 population in the blood and the intestinal mucosa of these
patients (12, 67), while Th17 cells are preferentially depleted in
other patient groups (5, 42, 46, 49, 59). The presence of Gag-
specific Th17 effectorsmay have beneficial effects, by contributing
either directly or indirectly to HIV control and by helping main-
tain the integrity of mucosal surfaces. On the other hand, the
activation of Th17 effectors may also foster the low-grade inflam-
matory condition that persists in HIV controllers (6, 30, 58), with
possible deleterious consequences such as increased susceptibility
to cardiovascular disease in the long term (14). Analysis of poly-
functionality showed thatmost of the IL-17CD4T cells inHIV
controllers did not produce IFN-, indicating the presence of typ-
ical Th17 cells, rather than cells of themixedTh1Th17 phenotype.
We cannot rule out that Th17 cells produced other cytokines that
were not tested in the same panel as IL-17, such as IL-2 or TNF-,
butwe noted that these cells did not produce IL-21, suggesting low
polyfunctionality. The c family cytokine IL-21, when produced
by Th17 cells, acts in an autocrine fashion to amplify and stabilize
IL-17 production via the activation of the transcription factor
STAT3 (76). The lack of bifunctional IL-17 IL-21 cells suggests
that Th17 differentiation may be only transient, reinforcing the
FIG 6 Correlations between the percentages of Gag293-specific cells detected by tetramer staining and by intracellular cytokine staining (ICS). (A) Correlation
between the percentage of Gag293 tetramer-positive CD4 T cells (%Gag293 Tet) (x axis) and the percentage of IFN- secreting CD4 T cells detected by ICS
after Gag293 stimulation (%IFN-) (y axis) in the HIV controller (HIC) group. (B) Correlation between the percentages of Gag293 Tet cells and Gag293-
specific IFN- secreting CD4T cells in theHAART group. (C) Correlation between the percentages of Gag293 Tet cells andGag293-specific IL-17--secreting
CD4T cells in theHIC group. (D)Correlation between the percentages ofGag293Tet cells andGag293-specific IL-17--secretingCD4T cells in theHAART
group. The nonparametric Spearman correlation coefficient R and the P value are shown for each correlation.
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notion that the predominant helper differentiation pattern is,
rather, Th1 in HIV controllers.
TheMHCclass II tetramer analysis showed that the population
of HIV-specific CD4 T cells persisted at relatively high levels in
peripheral blood in the HIV controller group, with a median of
0.12% of CD4 T cells directed against the single Gag293 peptide.
Of note, this number is aminimal estimate, given that Gag293 can
be presented by other HLA-DR alleles than those studied and also
byHLA-DQmolecules (35, 38). The finding of a high frequency of
Tet cells in HIV controllers supports the notions that HIV-spe-
cific CD4 T cells are spared from depletion in situations of con-
trolled viremia and that a persistently active cellular response sus-
tains the pool of specific cells. The frequency of Gag293-specific
cells was significantly lower in treated patients, though it was in-
triguing that it could remain as high as in controllers for a few
individuals. Two studies have shown that the frequency of Tet
Gag-specific CD4 T cells is generally low in treated patients and
can rebound upon short-term-therapy interruption, with a shift
toward a more effector differentiation pattern accompanying the
resumption of viral replication (68, 69). We cannot rule out that
some of the treated patients may have undergone blips in viral
replication that would have escaped detection but would have
been sufficient to stimulate the expansion of specific cells. How-
ever, we did not detect a higher proportion of Tet cells with an
effector memory phenotype in patients with a higher frequency of
Tet cells (not shown). Rather, central memory cells predomi-
nated in the Tet populations, both in theHAART and in theHIC
group, consistent with a low antigenemia. A possibility is that
HIV-specific central memory cells may expand in some of the
patients treated in the long term, which would be consistent with
a partial recovery of proliferative responses (24, 71). Importantly,
increased Tet frequency did not correlate with increased IFN-
secretion frequency in the HAART group, while it did so in the
HIC group. Thus, Gag293-specific cells appeared to differ func-
tionally, if not phenotypically, between the two groups, with a
persistence of Th1 effector function inHIV controllers. A caveat of
this interpretation is that we did not directly detect cytokine pro-
duction within the Tet population, due to a reduced sensitivity
of Tet cell detection after intracellular cytokine staining. How-
ever, since the frequency of IFN- producer cells was minimal in
treated patients, it is reasonable to assume that in these patients
the vast majority of Tet cells would fail to produce IFN- upon
restimulation with the Gag293 peptide.
Several reasons may account for the persistence of an effector
function in HIV controllers but not in patients treated in the long
term. A straightforward explanation could be the capacity of HIV
controller memory CD4 T cells to reactivate upon encountering
very small amounts of viral antigens. Indeed, we recently reported
that a subset of CD4 T cells with a high avidity for the Gag293
peptide could be detected exclusively in primary CD4T cell lines
derived from HIV controllers and not in those from treated pa-
tients (74). The presence of a pool of high-avidity cells could ex-
plain the persistence of Th1 effectors that would remain activated
in the presence of very low viremia. Such cells may play a key role
in viral control by sensing local blips in viral replication and by
triggering a rapid antiviral recall response that would ensure a
return to baseline viremia. The secretion of cytokines by high-
avidity cells may also help explain the low-grade chronic immune
activation that persists in HIV controllers (6, 30, 58), a phenom-
enon that could lead to deleterious consequences in the very long
term (14). Future studies should help determine whether high-
avidity CD4 T cells can be detected directly in the peripheral
blood ofHIV controllers, andwhether such cells have a phenotype
indicative of chronic reactivation. Another possible explanation
for the persistence of Th1 responses in the controller groupmay be
the presence of slightly higher levels of residual viral replication in
HIV controllers than in patients treated in the long term. How-
ever, analyses based on high-sensitivity viral load assays have not
revealed so far a clearly higher viral burden in the HIV controller
population. CirculatingHIV-1 RNA can be detected in the plasma
of most HIV controllers, but median viral RNA levels appear ex-
tremely low (2 copies/ml) (54). Patients treated in the long term
harbor a residual viremia of the same order of magnitude (1.5
copies/ml) (53). On the other hand, correlations between viral
load and both humoral and cellular responses have been reported
in HIV controllers (31, 54), suggesting that the availability of viral
antigensmay influence the level of recall responses. Thus, it will be
important in future studies to determine the respective roles of
antigen levels and antigen sensitivity of T cells in the persistence of
Th1 responses in HIV controllers.
Negative immunoregulationmay also contribute to the lack of
Th1 cytokine production by CD4 T cells from treated patients.
Prior to therapy initiation, these patients experienced years of ac-
tive HIV replication, which inflicted multiple insults on the im-
mune system, including the deletion of key populations of CD4
T cells but also the overstimulation and exhaustion of the remain-
ing pool of HIV-specific cells. The expression of inhibitory recep-
tors such as programmed death 1 (PD-1), CTLA-4, and T cell
immunoglobulin mucin 3 (TIM-3) is markedly increased on
HIV-specific CD4 T cells of viremic patients and is not entirely
normalized after therapy, which may limit the capacity of specific
CD4 T cells to reactivate upon stimulation with HIV antigens
(37, 39, 57). It is also noteworthy that IL-10 was the only cytokine
that was produced by CD4 T cells more in the HAART group
than in the HIC group. The difference was significant for Gag
peptides but also, intriguingly, for responses to CMV peptides.
IL-10 production can be viewed as a physiological response con-
tributing to the containment of excessive Th1 responses. For in-
stance, Th1 cells directly convert to IL-10-producing regulatory T
cells in models of tolerance induction (21). In viremic HIV infec-
tion, IL-10 is abundantly produced by multiple cell types, includ-
ing monocytes, B cells, and T cells, with monocytes being major
contributors (7, 65). IL-10 causes a reversible impairment of
CD4 T cell functions such as proliferation and secretion of other
cytokines (7, 65, 72). Our findings suggest that IL-10 production
still contributes to the dysfunction of HIV-specific cells in treated
HIV infection and that negative immunoregulation by IL-10 may
also extend to responses against other pathogens such as CMV. In
contrast, HIV controllers may harbor persistently high levels of T
cell effectors directed against other intracellular pathogens, as sug-
gested by studies documenting higher CMV-specific CD4 re-
sponses (32) and a possibly higher clearance rate of hepatitis C
virus (HCV) infection (66) in HIV controllers than in uninfected
individuals. The persistence of Th1 effectors directed against HIV
may prime the immune system of controllers for a more efficient
response to other viruses, for instance through a chronic release of
IFN- that would facilitate the differentiation of Th1 cells of other
specificities through the bystander effect. Alternatively, HIV con-
trollers may harbor genetic traits that promote Th1 differenti-
ation, which may be explored in large-scale genetic studies.
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In conclusion, spontaneous HIV control is associated with the
persistence of highly functional Th1 effectors, whereas pharmaco-
logical HIV control leads to a dampening of CD4 effector func-
tions. The fact that CD4 responses are not entirely lost but, rather,
dysfunctional in treated patients raises the possibility of reawak-
ening these responses through immunotherapeutic intervention.
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